GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Read more
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release Read more
Screening for Colonization with Resistant Enterobacterales in Neutropenic Patients with Hematologic Malignancies (SCENE) Read more
RAPA-501-ALLO-COVID-19, PI: Dr. Donato, Title: Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-Allo) Therapy for Severe, Post-Intubation Stage 3 COVID-19 Disease Read more
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE Read more
Phase I Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) for Amyotrophic Lateral Sclerosis Read more
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release. Read more
